CDDO-imidazolide mediated inhibition of malignant cell growth in Waldenström macroglobulinemia.

@article{Elsawa2008CDDOimidazolideMI,
  title={CDDO-imidazolide mediated inhibition of malignant cell growth in Waldenstr{\"o}m macroglobulinemia.},
  author={Sherine F. Elsawa and Anne J. Novak and Deanna M. Grote and Marina Konopleva and Michael Andreeff and Thomas E Witzig and Stephen M Ansell},
  journal={Leukemia research},
  year={2008},
  volume={32 12},
  pages={
          1895-902
        }
}
Waldenström macroglobulinemia (WM) is a B-cell malignancy that remains incurable. Synthetic triterpenoids (ST), 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO), its methyl ester derivative (CDDO-Me) and imidazolide derivative (CDDO-Im) induce cell death and inhibit growth of various malignancies and hold promise as treatment for cancer patients. We examined the therapeutic potential of these compounds in WM. All three forms of CDDO induced equal toxicity in BCWM.1 cells. In malignant B… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 34 REFERENCES

The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2003
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL